FDA Extends Review Date of Pfizer RA Drug Tofacitinib by Three Months

Drug Industry Daily
A A
The FDA has pushed back its action date on Pfizer’s rheumatoid arthritis (RA) drug tofacitinib by three months to review additional data analyses recently submitted by Pfizer.

To View This Article:

Login

Subscribe To Drug Industry Daily